N/A N=62 REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Carcinoma, Renal Cell
Primary: Time to Complete Remission of Lesions — 10.9; 15.7 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=142 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Renal Cell Carcinoma
Primary: PFS (Progression-Free Survival) — 27.71 Weeks
N/A N=1,349 Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
Renal Cell Carcinoma
Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days
Phase 1 N=5 TIL Therapy for Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Number of Patients in Which the Treatment Was Tolerable — 5 Participants
Phase 2 N=25 SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients
Kidney Cancer Metastatic · Kidney Cancer · Kidney Cancer, Stage IV
Primary: Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0 — 9 Participants
N/A N=77 Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients
Complete Remission in Renal Cell Carcinoma
Primary: Time to Diagnose Metastatic Renal Cell Carcinoma — 3.79; 0.21 Years — p=<0.001
Phase 2 N=50 Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: Progression Free Survival (PFS) — 11 months
N/A N=19 Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Kidney Cancer · Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma
Primary: Initial Objective Response- First Participation — 5; 1; 7; 4 Participants
Phase 2 N=164 Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Primary: 1-year Progression Free Survival (PFS) Rate for ccRCC Patients — 34.6; 53.8; 33.3; 75 Percentage of participants
Phase 2 N=21 Neoadjuvant Pazopanib in Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Response Rate — 8 Participants
Phase 1 N=25 Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
Renal Cell Cancer
Primary: Metabolic Response — 5 participants
Phase 2 N=225 GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Overall Response by RECIST Criteria — 3; 75; 101; 24 participants
N/A N=618 Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy
Renal Cell Carcinoma
Primary: Follow-up Duration — 1.07 years
Phase 2 N=106 A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
Carcinoma, Renal Cell
Primary: Number of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST) — 35 participants
N/A N=1,769 Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Metastatic Renal Cell Carcinoma
Primary: Overall Survival — 52.1; 31.5; 9.8 months
Phase 3 N=435 Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Progression-free Survival — 9.2; 4.2 months — p=.0000001
Phase 2 N=168 BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 2.63; 4.11; 4.17 Months
Phase 2 N=30 High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
Metastatic Clear Cell Renal Cell Carcinoma
Primary: Response Rate — 4 Participants
Phase 3 N=626 Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
Carcinoma, Renal Cell · Kidney Neoplasms
Primary: Overall Survival (OS) — 7.3; 10.9; 8.4 months — p=0.0252
N/A N=448 SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Number of Participants With Categorical Best Overall Response — 13; 130; 120; 58 Participants
Phase 2 N=62 Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment
Advanced Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 7.5; 4.6; 6.8 Months
Phase 3 N=1,538 A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma (RCC) · Cancer
Primary: Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo — NA; NA months — p=0.1649
Phase 2 N=123 The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Objective Response in ISM Good Risk Group — .23 proportion of participants — p=0.042
Phase 2 N=92 Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
Renal Cell Carcinoma
Primary: Best Response by RECIST v1.0 — 0; 1; 0; 1 Participants
Phase 2 N=20 Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Primary: Percentage of Participants Who Achieved a Point in Time Objective Response (Either Complete or Partial Response [CR or PR]) Prior to Surgery — 2; 0 Participants
Phase 2 N=146 A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Renal Cell Cancer
Primary: Progression-Free Survival (PFS) - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months — 58.2; 28.9 percentage of participants
Phase 3 N=864 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
Kidney Cancer
Primary: Disease-free Survival — 192; 197 Participants — p=0.737
Phase 2 N=134 Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Progression-free Survival (PFS) - All Participants — 7.4 months
N/A N=102 Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC
Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — NA months
Phase 2 N=55 Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Overall Response Rate — 27 percentage of patients